Design of experiments utilization to map the processing capabilities of a micro-spray dryer: particle design and throughput optimization in support of drug discovery.

There has been a growing interest in amorphous solid dispersions for bioavailability enhancement in drug discovery. Spray drying, as shown in this study, is well suited to produce prototype amorphous dispersions in the Candidate Selection stage where drug supply is limited. This investigation mapped the processing window of a micro-spray dryer to achieve desired particle characteristics and optimize throughput/yield. Effects of processing variables on the properties of hypromellose acetate succinate were evaluated by a fractional factorial design of experiments. Parameters studied include solid loading, atomization, nozzle size, and spray rate. Response variables include particle size, morphology and yield. Unlike most other commercial small-scale spray dryers, the ProCepT was capable of producing particles with a relatively wide mean particle size, ca. 2-35 µm, allowing material properties to be tailored to support various applications. In addition, an optimized throughput of 35 g/hour with a yield of 75-95% was achieved, which affords to support studies from Lead-identification/Lead-optimization to early safety studies. A regression model was constructed to quantify the relationship between processing parameters and the response variables. The response surface curves provide a useful tool to design processing conditions, leading to a reduction in development time and drug usage to support drug discovery.

Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA.

A tumor targeted mesoporous silica nanoparticles (MSN)-based drug delivery system (DDS) was developed for inhalation treatment of lung cancer. The system was capable of effectively delivering inside cancer cells anticancer drugs (doxorubicin and cisplatin) combined with two types of siRNA targeted to MRP1 and BCL2 mRNA for suppression of pump and nonpump cellular resistance in non-small cell lung carcinoma, respectively. Targeting of MSN to cancer cells was achieved by the conjugation of LHRH peptide on the surface of MSN via poly(ethylene glycol) spacer. The delivered anticancer drugs and siRNA preserved their specific activity leading to the cell death induction and inhibition of targeted mRNA. Suppression of cellular resistance by siRNA effectively delivered inside cancer cells and substantially enhanced the cytotoxicity of anticancer drugs. Local delivery of MSN by inhalation led to the preferential accumulation of nanoparticles in the mouse lungs, prevented the escape of MSN into the systemic circulation, and limited their accumulation in other organs. The experimental data confirm that the developed DDS satisfies the major prerequisites for effective treatment of non-small cell lung carcinoma. Therefore, the proposed cancer-targeted MSN-based system for complex delivery of drugs and siRNA has high potential in the effective treatment of lung cancer.

Labile catalytic packaging of DNA/siRNA: control of gold nanoparticles "out" of DNA/siRNA complexes.

A novel approach was developed to efficiently package and deliver nucleic acids with low generation polypropylenimine (PPI) dendrimers by using Au nanoparticles as a "labile catalytic" packaging agent. The gold nanoparticles (Au NPs) helped low generation dendrimers to package nucleic acids into discrete nanoparticles but are not included in the final DNA/siRNA complexes. Therefore it becomes possible to eliminate the potential toxic problems associated with Au NPs by selectively removing the Au NPs from the resulting nucleic acid complexes before their delivery to targeted cells. This is a new concept in using inorganic engineered nanoparticles in nucleic acid packaging and delivery applications. Furthermore, compared to the siRNA nanostructures (mainly randomly aggregated nanofibers) fabricated by low generation dendrimer alone (Generation 3), the siRNA nanoparticles packaged using this novel approach (by Au NPs modified with G3 PPI) can be internalized by cancer cells and the delivered siRNAs can efficiently silence their target mRNA. The efficiency of mRNA silencing by this novel approach is even superior to higher generation dendrimers (Generation 5).

DNA and carbon nanotubes as medicine.

The identification of disease-related genes and their complete nucleotide sequence through the human genome project provides us with a remarkable opportunity to combat a large number of diseases with designed genes as medicine. However, gene therapy relies on the efficient and nontoxic transport of therapeutic genetic medicine through the cell membranes, and this process is very inefficient. Carbon nanotubes, due to their large surface areas, unique surface properties, and needle-like shape, can deliver a large amount of therapeutic agents, including DNA and siRNAs, to the target disease sites. In addition, due to their unparalleled optical and electrical properties, carbon nanotubes can deliver DNA/siRNA not only into cells, which include difficult transfecting primary-immune cells and bacteria, they can also lead to controlled release of DNA/siRNA for targeted gene therapy. Furthermore, due to their wire shaped structure with a diameter matching with that of DNA/siRNA and their remarkable flexibility, carbon nanotubes can impact on the conformational structure and the transient conformational change of DNA/RNA, which can further enhance the therapeutic effects of DNA/siRNA. Synergistic combination of the multiple capabilities of carbon nanotubes to deliver DNA/siRNAs will lead to the development of powerful multifunctional nanomedicine to treat cancer or other difficult diseases. In this review, we summarized the current studies in using CNT as unique vehicles in the field of gene therapy.

The electronic role of DNA-functionalized carbon nanotubes: efficacy for in situ polymerization of conducting polymer nanocomposites.

We have found that the polymerization process was 4,500 times faster when a self-doped polyaniline nanocomposite was fabricated using in situ polymerization in the presence of single-stranded DNA-dispersed and -functionalized single-walled carbon nanotubes (ssDNA-SWNTs). More importantly, the quality of the composite was significantly improved: fewer short oligomers were produced, and the self-doped polyaniline backbone had a longer conjugation length and existed in the more stable and conductive emeraldine state. The functionality of the boronic acid group in the composite and the highly improved electronic performance may lead to broad applications of the composite in flexible electronic devices. Blending of preformed polymer with carbon nanotubes is straightforward and widely used to fabricate nanocomposites. We demonstrate that this simple mixing approach might not fully and synergistically combine the merits of each individual component. Surprisingly, these advantages also cannot be obtained using in situ polymerization with preoxidized ssDNA-SWNTs, which is renowned as the "seed" method for production of conducting-polymer nanowires. The electronic structures of the carbon nanotubes and the monomer-nanotube interaction during polymerization greatly impact the kinetics of nanocomposite fabrication and the electronic performance of the resulting composites.

Development of a pharmaceutical cocrystal of a monophosphate salt with phosphoric acid.

We report the first case of a pharmaceutical cocrystal formed between an inorganic acid and an active pharmaceutical ingredient (API), which enabled us to develop a stable crystalline and bioavailable solid dosage form for pharmaceutical development where otherwise only unstable amorphous free form or salts could have been used.